The all-new T65 Coil is the first release in our upcoming T-series, a new generation of lighter, high-performance cooled coils.
MagVenture TMS Therapy™ system has been FDA-cleared to treat Major Depressive Disorder (MDD) with comorbid anxiety symptoms in adults. This allows providers to treat adult MDD patients experiencing symptoms of anxiety, a highly prevalent and clinically challenging population
We would like to express our appreciation to everyone who attended our “TMS and Addiction” webinar with Dr. Antonello Bonci on September 4th.
Auditory verbal hallucinations are a major burden for patients with schizophrenia spectrum disorder and are often resistant to medication and psychotherapy. A new study published in The Lancet Psychiatry reports that bilateral continuous theta burst stimulation (cTBS) can offer real relief.
MagVenture will once again support the TMS certification course and masterclass organized by Brainclinics Foundation in Nijmegen, the Netherlands, from September 30 to October 2, 2025.
MagVenture will be participating in WCP in Prague this year.
Last year this course sold out very quickly. If you have a customer who would like to attend, please get in touch with your MagVenture representative to discuss what discount options have been put in place for MagVenture’s customers.
We are pleased to announce an exceptional collaboration between Neurointelligence, MagVenture, and the Academy of Brain Stimulation, in collaboration with the Sakina Center and SEHA Center, to bring you the most comprehensive International TMS Certification Course ever offered in the Middle East.
The MR4 2025 Summer Release brings major advancements in motion data quality, workflow efficiency, and visual analysis.
A new milestone in TPS research for Alzheimer’s has been achieved! For the first time, scientists have conducted a detailed animal study on healthy and transgenic mice with Alzheimer’s to explore the effects of Transcranial Pulse Stimulation (TPS).